Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learned: Table 1.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

(2015) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy

(2014) O. Bylicki et al.   ANNALS OF ONCOLOGY

Patient-reported outcomes in randomised controlled trials of gynaecological cancers: Investigating methodological quality and impact on clinical decision-making

(2014) Fabio Efficace et al.   EUROPEAN JOURNAL OF CANCER

“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?

(2014) Alison Davis et al.   GYNECOLOGIC ONCOLOGY

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

(2014) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers

(2014) Melanie Calvert et al.   PLoS One

SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials

(2013) An-Wen Chan et al.   ANNALS OF INTERNAL MEDICINE

Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper

(2013) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

Reporting of Patient-Reported Outcomes in Randomized Trials

(2013) Melanie Calvert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Research into palliative care in sub-Saharan Africa

(2013) Richard Harding et al.   LANCET ONCOLOGY

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

(2012) Nicoletta Colombo et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards

(2012) Michael Brundage et al.   QUALITY OF LIFE RESEARCH

Clinical Trials in Recurrent Ovarian Cancer

(2011) Michael Friedlander et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer

(2011) Gavin C.E. Stuart et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer

(2011) Stan B. Kaye et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers

(2010) Michael Brundage et al.   QUALITY OF LIFE RESEARCH

Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG

(2010) Heather-Jane Au et al.   Expert Review of Pharmacoeconomics & Outcomes Research